Navigation Links
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Date:10/30/2008

Driven by patent expiries, development of novel therapeutics, and the rapidly aging population, the world market for anticoagulants is projected to exceed $12 billion by 2015. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants.

San Jose, CA (PRWEB) October 30, 2008 -- The unmet medical needs of available anticoagulants offer ample scope for development in the world anticoagulants market. Continuous research and development is expected to result in novel therapies with superior therapeutic efficiency, and minimum side effects. These advanced therapeutics offer promising market prospects. Exanta, for instance, represents a cutting edge direct thrombin inhibitor that flaunts the potential to kindle demand patterns, dethrone warfarin's dominance, and challenge the supremacy of low molecular weight heparins. Identification of new indications for existing, and emerging therapies is expected to help open up brighter prospects for further growth.

Factor Xa inhibitors (oral and injectable) and direct thrombin inhibitors (oral and injectable) are among the new class of thrombin antagonists that are being evaluated for both existing as well as newer indications. Development of products for specific market niches, like, anticoagulation therapies for ischemic stroke, is additionally expected to result in expanded opportunities. Patent expiries of drugs like "Coumadin" offer a lucrative business case for generic drug manufacturers. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.

The United States dominates the world anticoagulants market, with a share of nearly 50%, as stated by Global Industry Analysts, Inc. Strong double digit growth is expected to stem from the injectable anticoagulants market, with the United States setting the pace of growth with projected CAGR in excess of 15.1% over the period of 2000 through 2010. Market for injectable anticoagulants is dominated by low molecular weight heparin (LMWH). Strong growth in LMWH market is expected to push sales of injectable anticoagulants to US$6.6 billion by 2010. Japanese oral anticoagulants market is estimated to be worth US$38.3 million. In Europe, France represents the largest market with a 23.8% share.

Major market participants profiled include AstraZeneca PLC, Barr Laboratories Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., and Sanofi-Aventis.

The report titled "Anticoagulants: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, drivers, issues, challenges, and research and development activities. Richly annotated with authoritative, and unbiased commentaries, and hard-to-find statistical facts, the report provides unequivocal views on future potential while throwing light on the prevailing climate in key regional markets. Product markets analyzed in the report include Oral, and Injectable (Unfractionated Heparin, and Low Molecular Weight Heparin). Latent demand patterns in product markets are quantified across major geographic market verticals including the United States, Japan, France, Germany, United Kingdom, Italy, and Spain, among others for the period 2000-2015. Also provided in the report is an enumeration of recent mergers, acquisitions, and other strategic industry activities.

For more details about this research report, please visit
http://www.strategyr.com/Anticoagulants_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.StrategyR.com/

###

Read the full story at http://www.prweb.com/releases/anticoagulants/injectable_oral/prweb1542674.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Repair and healing of osteoporotic fractures a focus of upcoming IOF World Congress on Osteoporosis
2. Considering Revision Surgery? Board Certified Plastic Surgeon and Washington DC-based Dr. Mark E. Richards Pioneers Facelift Revisions Attracting Patients Worldwide
3. WorldHeart Announces Effectiveness of Reverse Stock Split
4. Our cheatin brain: The brains clever way of showing us the world as a whole
5. Several US Children Among Worldwide Heroes for Inspirational Fundraising Efforts with Celine Dion
6. World Biochips Market to Reach $3.4 billion by 2012, According to New Report by Global Industry Analysts, Inc.
7. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
8. National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
9. The Wireless World: Untethered Opportunities
10. This Holiday Season, Give a Gift that Does a World of Good
11. HTH Worldwide Unveils First Digital Healthcare Card
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
World Anticoagulants Market to Exceed $12 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... CLEMENTE, Calif. , June 24, 2016  American Respiratory Labs ... company, is now able to perform sophisticated lung assessments in patients, ... Technologies , Inc. Patients are no longer limited ... ndd,s EasyOne PRO ® , ARL patients like Jeanne R. of ... done in the comfort of her own home. ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology: